Combination chemotherapy of S-1 and low-dose cisplatin for advanced gastric cancer

Gastric Cancer

Volumn 6, Issue SUPPL. 1, 2003, Pages 50-57

  Tsujitani, Shunichi ^a   Fukuda, Kenji ^a   Kaibara, Nobuaki ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Advanced gastric carcinoma; Cisplatin; Combination chemotherapy; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; TS 1;

ADULT; AGED; ANEMIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CONFERENCE PAPER; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GASTROINTESTINAL TOXICITY; HOSPITALIZATION; HUMAN; KIDNEY DISEASE; LEUKOPENIA; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; STOMACH CARCINOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING; VOMITING;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; JAPAN; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; OXONIC ACID; PERITONEAL NEOPLASMS; PYRIDINES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STOMACH NEOPLASMS; TEGAFUR; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 0038584861     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-003-0223-x     Document Type: Conference Paper

References (35)

1. Kelsen DP. Cancer of the stomach. In: DeVita VT, editors. Cancer, principles and practice of oncology. 4th Ed. Philadelphia: JB Lippincott; 1995. pp 838-48.
2. Wils J. The treatment of advanced gastric cancer. Semin Oncol 1996;23:397-406.
3. Sakata Y, Suzuki H. Do we have a strategy for gastrointestinal cancers at present and the future? Cancer Chemother 1995;10:169-80.
4. Moertel CG. Chemotherapy of gastrointestinal cancer. In: Tagnon HJ, Staquest MJ, editors. Recent advances in cancer treatment. New York: Raven; 1977. pp 311-23.
5. Beer M, Cocconi G, Ceci G, Varini M, Cavalli F. A phase II study of cisplatin in advanced gastric cancer. Eur J Cancer Clin Oncol 1983;19:717-20.
6. Miyamoto K, Yoshida S, Saito D, Shimada Y, Tajiri H, Yamaguchi H, et al. Pilot phase II study of cis-diaminedichloroplatinum (II) against metastatic gastric cancers. Jpn J Clin Oncol 1990;20:169-76.
7. Klein HO, Dias Wickramanayake P, Dieterle F, Mohr R, Oerkermann H, Brock J, et al. Chemotherapieprotokoll zur behandlung des metastasierenden Magenkarzinoms. Methitrexat, Adriamycin, und 5-fluorouracil. Dtsch Med Wochenschr 1982;107:1708-12.
8. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubin, and methotrexate in esophagogastric cancer. J Clin Oncol 1997;15:261-7.
9. Wils JA, Klein HO, Wagerer DJT, Bleiberg H, Reis H, Korsten F et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin: a step ahead in the treatment of gastric cancer: a trial of the EORTG. J Clin Oncol 1991;9:827-31.
10. Kelsen D, Atiq OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, et al. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992;10:541-8.
11. Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, et al. Phase II study with the combination of etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989;7:1310-17.
12. Lerner A, Gonin R, Steele GD Jr, Mayer J. Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial. J Clin Oncol 1992;10:536-40.
13. Lacave AJ, Baron FJ, Anton LM, Estrada E, De Sande LM, Palacio I, et al. Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial. Ann Oncol 1991;2:751-4.
14. Rougier P, Ducreux M, Mahjoubi M, Pignon JP, Bellefqih S, Oliveira J, et al. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas: a phase II trial with prognostic factor analysis. Eur J Cancer 1994;30:1263-9.
15. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Cutsem EV, et al. Final results of randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the EORTG. J Clin Oncol 2000;18:2648-57.
16. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, et al. Antitumor activity of 1 M tegafur - 0.4 M 5-chloro-2,4-dihydroxypyridine - 1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996;56:2602-6.
17. Shirasaka T, Shimamoto S, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996;7:548-57.
18. Takechi T, Nakano K, Uchida J, Mita A, Toko K, Takeda S, et al. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 1997;39:205-11.
19. Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Mitachi Y, et al. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. Oncology 1999;57:202-10.
20. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur - 0.4 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-20.
21. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, 2nd English edition. Gastric Cancer 1998;11:10-24.
22. World Health Organization. WHO handbook for reporting results of cancer treatment. WHO offset publication no. 48. Geneva: World Health Organization; 1979.
23. Japanese Research Society for Gastric Cancer, editors, Japanese classification of gastric carcinoma. 1st English Ed. Tokyo: Kanehara; 1995.
24. Tobinai K, Kohno A, Shimada Y, Watanabe T, Tamura T, Takeyama K, et al. Toxicity grading criteria of Japan Clinical Oncology Group. Jpn J Clin Oncol 1993;23:250-7.
25. Shimada Y, Shirao K, Ohtsu A, Hyodo I, Saito H, Yamanishi N, et al. Phase III study of UFT + MMC versus 5-FU + CDDP versus 5-FU alone in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 1999;18:1043.
26. Chung YS, Yamashita Y, Nakata B, Nitta A, Inoue T, Hirayama K, et al. Combination therapy of 5-FU and low dose CDDP for advanced and recurrent gastric cancer. Jpn J Cancer Chemother 1995;22:149-51.
27. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000;58:191-7.
28. Saikawa Y, Kanai T, Kawano Y, Otani Y, Kubota T, Kitajima M. A novel combined chemotherapy using TS-1 and low-dose cisplatin against liver metastasis of gastric cancer. Jpn J Cancer Chemother 2002;29:1241-5.
29. Gomi T, Ohtoshi M, Tamaki N, Momoi H, Kanaya S, Katayama T, et al. Three cases of advanced gastric cancer treated by TS-1 in combination with low-dose cisplatin. Jpn J Cancer Chemother 2002;29:301-4.
30. Kamata T, Hayashi Y, Minatoya G, Michiwa Y, Onishi I, Takeda T, et al. A pilot study of low-dose TS-1 and cisplatin combination chemotherapy for advanced gastric cancer. Jpn J Cancer Chemother 2001;28:1419-22.
31. Iwazawa T, Kinuta M, Yano H, Matsui S, Tamagaki S, Yasue A, et al. An oral anticancer drug, TS-1, enabled a patient with advanced gastric cancer with Virchow's metastasis to receive curative resection. Gastric Cancer 2002;5:96-101.
32. Ohtsu A, Boku N, Nagashima F, Koizumi W, Tanabe S, Saigenji K, et al. A phase I/II study of S-1 plus cisplatin in patients with advanced gastric cancer (abstract). Proc Am Soc Clin Oncol 2001;20:165.
33. Yonemura Y, Sawa T, Kinoshita K, Matsuki N, Fushida S, Tanaka S, et al. Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg 1993;17:256-61.
34. Nakajima T, Ota K, Ishihara S, Oyama S, Nishi M, Ohashi Y, et al. Combined intensive chemotherapy and radical surgery for incurable gastric cancer. Ann Surg Oncol 1997;4:203-8.
35. Yoshikawa T, Kanari M, Tsuburaya A, Kobayashi O, Sairenji M, Motohashi H, et al. Advanced gastric carcinoma successfully treated with TS-1 as neoadjuvant chemotherapy. Gastric Cancer 2000;3:171-5.